<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02710708</url>
  </required_header>
  <id_info>
    <org_study_id>18261</org_study_id>
    <nct_id>NCT02710708</nct_id>
  </id_info>
  <brief_title>YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China</brief_title>
  <official_title>Single-arm, Open-label, Interventional Study to Observe the Safety and Efficacy Profile of the Combined Oral Contraceptive YAZ®, a 24-day Cyclic Regimen Containing Drospirenone 3 mg and Ethinyl Estradiol 20 µg During a Treatment Duration of 6 Cycles: a Post-authorization Safety and Efficacy Study in Chinese Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the safety profile of YAZ in Chinese women, including
      adverse drug reactions (ADRs).

      The secondary objectives are to investigate the rate of unintended pregnancies, the cycle
      control for subjects with and without preceding abortion, the bleeding pattern of subjects
      with and without preceding abortion (including the abortion-related bleeding pattern) and the
      efficacy in moderate acne vulgaris.

      Another objective is to investigate the effect on dysmenorrhea.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 27, 2016</start_date>
  <completion_date type="Anticipated">July 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse drug reactions (ADRs)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of unintended pregnancies as measured by the Pearl Index (PI)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding days</measure>
    <time_frame>Up to 90 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding episodes</measure>
    <time_frame>Up to 90 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Acne lesions</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of pain during menstruation measured by visual analog scale (VAS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2002</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Ethinyl Estradiol 20 (EE20)/DRSP (YAZ, BAY86-5300)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chinese women between 18 and 45 years old inclusive (smokers not older than 35 years old) requesting oral contraception who have no contraindication to YAZ will be recruited for the study. Women who underwent surgical or medical abortions will also be recruited.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EE20/DRSP (YAZ, BAY86-5300)</intervention_name>
    <description>YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets</description>
    <arm_group_label>Ethinyl Estradiol 20 (EE20)/DRSP (YAZ, BAY86-5300)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent

          -  Chinese female subjects requesting oral contraception, including subjects who
             underwent abortion (medical or surgical)

          -  Planned use of combined oral contraceptives for at least 6 cycles

          -  Age: 18 to 45 years (inclusive); smokers must not be older than 35 years at the time
             of informed consent

          -  At least 4 weeks postpartum for women who are not breastfeeding or after a second
             trimester abortion

        Exclusion Criteria:

          -  Evidence or suspicion of incomplete abortion (medical abortion subjects must have
             complete abortion confirmed by ultrasound [endometrial thickness ≤ 15 mm]).

          -  Pregnancy or lactation

          -  Menstrual disorders consistent with ovarian failure (eg, oligomenorrhea, amenorrhea,
             hypomenorrhea)

          -  Abuse of alcohol, drugs, or medicine (eg, laxatives)

          -  Inability to cooperate with the study procedures for any reason (eg, language
             comprehension, psychiatric illness, inability to get to the study site).

          -  Any diseases or conditions that can compromise the function of body systems and could
             result in altered absorption, excessive accumulation, impaired metabolism, or altered
             excretion of the study medication

          -  Any diseases or conditions that might interfere with the conduct of the study or the
             interpretation of the results

          -  Any contraindication to YAZ according to the Chinese label, such as:

               -  Renal impairment

               -  Adrenal insufficiency

               -  A high risk of arterial or venous thromboembolic diseases. Examples include
                  subjects who are known to:

                    -  Have deep vein thrombosis or pulmonary embolism, now or in the past

                    -  Have cerebrovascular disease

                    -  Have coronary artery disease

                    -  Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (eg,
                       subacute bacterial endocarditis with valvular disease, or atrial
                       fibrillation)

                    -  Have inherited or acquired hypercoagulopathies

                    -  Have uncontrolled hypertension

                    -  Have diabetes mellitus with vascular disease

                    -  Have headaches with focal neurological symptoms or have migraine headaches
                       with or without aura if over age 35

               -  Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the
                  past

               -  Liver tumors, benign or malignant, or liver disease

          -  Hypersensitivity to any ingredient of the study drug

          -  Undiagnosed abnormal genital bleeding

          -  Sterilized subjects or concomitant use of other hormonal contraception, intrauterine
             device (IUD), or intrauterine system (IUS) during the study

          -  For subjects qualifying for the moderate acne subgroup:

               -  Subjects with acne and atopy, comedonal acne or acne conglobata, sandpaper acne
                  or acne with multiple large nodes, cysts, fistular comedones, or abscessing
                  fistular ducts

               -  Use of preparations that have an acne-inducing effect (eg, iodinated or bromated
                  drugs, tuberculostatics, lithium, vitamin B1 [&gt;1.5 mg daily], B6 [&gt;2 mg daily],
                  B12 [&gt;6 µg daily], corticoids, adrenocorticotropic hormone anabolics, quinine,
                  disulfiram, methoxypsoralene, phenobarbital, phenytoin, trimethadione, thyroid
                  depressants, and certain oily cosmetics)

               -  Subjects undergoing systemic acne treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510405</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510623</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liuzhou</city>
        <state>Guangxi</state>
        <zip>545006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050035</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changsha</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yueyang</city>
        <state>Hunan</state>
        <zip>414000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <zip>213003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Weifang</city>
        <state>Shandong</state>
        <zip>261031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Weifang</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zibo</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610091</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Urumchi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100026</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100123</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2016</study_first_submitted>
  <study_first_submitted_qc>March 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2016</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>birth control,</keyword>
  <keyword>contraceptives safety,</keyword>
  <keyword>contraceptives efficacy,</keyword>
  <keyword>moderate acne vulgaris</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

